Chronic kidney disease growth factors in renal fibrosis

被引:89
作者
Boor, Peter [1 ,2 ,3 ]
Floege, Juergen [1 ]
机构
[1] Rhein Westfal TH Aachen, Dept Nephrol, D-52074 Aachen, Germany
[2] Rhein Westfal TH Aachen, Inst Pathol, D-52074 Aachen, Germany
[3] Comenius Univ, Inst Mol Biomed, Bratislava, Slovakia
关键词
bone morphogenic protein 7; connective tissue growth factor; growth factors; platelet-derived growth factor; transforming growth factor-beta; vascular endothelial growth factor; BONE MORPHOGENIC PROTEIN-7; UNILATERAL URETERAL OBSTRUCTION; TO-MESENCHYMAL TRANSITION; HUMAN MONOCLONAL-ANTIBODY; RAT REMNANT KIDNEY; I RECEPTOR KINASE; TUBULOINTERSTITIAL FIBROSIS; DIABETIC-NEPHROPATHY; PDGF-D; EXPERIMENTAL GLOMERULONEPHRITIS;
D O I
10.1111/j.1440-1681.2011.05487.x
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
1. The common pathological alteration in virtually every progressive chronic kidney disease (CKD) is renal fibrosis. 2. This review focuses on some growth factors, which are particularly well-established in contributing to fibrosis, such as the profibrotic, transforming growth factor-beta, and connective tissue growth factor (CTGF), as well as the antifibrotic, bone morphogenic protein 7. The role of other growth factors is only starting to emerge (e.g. platelet-derived growth factor), and the role of yet others remains unclear (e.g. vascular endothelial growth factor). 3. Whether circulating or excreted, growth factors might serve as biomarkers of renal fibrosis and CKD remains largely unanswered. 4. Animal studies suggest that manipulation of growth factors might be an effective treatment option for patients with renal fibrosis and CKD. So far, only inhibition of CTGF is being tested in patients with diabetic nephropathy.
引用
收藏
页码:391 / 400
页数:10
相关论文
共 96 条
[1]
Transforming growth factor beta and progression of renal disease [J].
August, P ;
Suthanthiran, M .
KIDNEY INTERNATIONAL, 2003, 64 :S99-S104
[2]
Altered bone and mineral metabolism in patients receiving imatinib mesylate [J].
Berman, E ;
Nicolaides, M ;
Maki, RG ;
Fleisher, M ;
Chanel, S ;
Scheu, K ;
Wilson, BA ;
Heller, G ;
Sauter, NP .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (19) :2006-2013
[3]
Regulation of PDGF and its receptors in fibrotic diseases [J].
Bonner, JC .
CYTOKINE & GROWTH FACTOR REVIEWS, 2004, 15 (04) :255-273
[4]
Treatment targets in renal fibrosis [J].
Boor, Peter ;
Sebekova, Katarina ;
Ostendorf, Tammo ;
Floege, Juergen .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (12) :3391-3407
[5]
PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis [J].
Boor, Peter ;
Konieczny, Andrzej ;
Villa, Luigi ;
Kunter, Uta ;
van Roeyen, Claudia R. C. ;
LaRochelle, William J. ;
Smithson, Glennda ;
Arrol, Sharon ;
Ostendorf, Tammo ;
Floege, Juergen .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (05) :1323-1331
[6]
Renal fibrosis: novel insights into mechanisms and therapeutic targets [J].
Boor, Peter ;
Ostendorf, Tammo ;
Floege, Juergen .
NATURE REVIEWS NEPHROLOGY, 2010, 6 (11) :643-656
[7]
PDGF-C Mediates Glomerular Capillary Repair [J].
Boor, Peter ;
van Roeyen, Claudia R. C. ;
Kunter, Uta ;
Villa, Luigi ;
Buecher, Eva ;
Hohenstein, Bernd ;
Hugo, Christian P. M. ;
Eriksson, Ulf ;
Satchell, Simon C. ;
Mathieson, Peter W. ;
Eitner, Frank ;
Floege, Juergen ;
Ostendorf, Tammo .
AMERICAN JOURNAL OF PATHOLOGY, 2010, 177 (01) :58-69
[8]
Patients with IgA nephropathy exhibit high systemic PDGF-DD levels [J].
Boor, Peter ;
Eitner, Frank ;
Cohen, Clemens D. ;
Lindenmeyer, Maja T. ;
Mertens, Peter R. ;
Ostendorf, Tammo ;
Floege, Juergen .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (09) :2755-2762
[9]
Polyclonal Immunoglobulin G Ameliorates the Course of Progressive Mesangioproliferative Glomerulonephritis in Rats [J].
Boor, Peter ;
Kunter, Uta .
KIDNEY & BLOOD PRESSURE RESEARCH, 2009, 32 (03) :169-174
[10]
TGF-β signaling in renal disease [J].
Böttinger, EP ;
Bitzer, M .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (10) :2600-2610